Phosphate Control in Peritoneal Dialysis Patients: Issues, Solutions, and Open Questions

Hyperphosphatemia is a common complication in advanced chronic kidney disease and contributes to cardiovascular morbidity mortality. The present narrative review focuses on the management of phosphatemia uremic patients receiving peritoneal dialysis. These frequently develop hyperphosphatemia since phosphate anion behaves as middle-size molecule despite its low molecular weight. Accordingly, patient transporter characteristics dialysis modalities prescriptions remarkably influence serum control. Given that removal often insufficient, especially lower transporters, are prescribed binders whose use primarily based clinical trials conducted hemodialysis because very few studies have been performed solely populations. A crucial role control among played by diet, which must help reducing phosphorous intake while preventing malnutrition. Moreover, residual renal function, preserved most patients, significantly maintaining balance. inadequate observed many highlights need for large well-designed including exclusively evaluate effects multiple therapeutic approach hard outcomes this high-risk population.